Scientists are investigating whether modern ailments are linked with NAD+/SIRT1 disturbances. What exactly does SIRT1 do and which factors might activate or block it? Read on to learn what the latest science suggests.
SIRT1 is a protein that removes acetyl groups from other proteins – and it requires NAD+ to function .
Recent studies have implicated SIRT1 in gene expression, metabolism, and aging. We can view SIRT1 as kind of like the car and NAD+ like the gas – the body needs both of them together to work effectively .
Scientists suspect that when proteins are undergoing stress, acetyl groups are added to them as a response to changes induced by inflammation and oxidation .
Sirtuins (like SIRT1) remove these acetyl groups to keep the protein in service. They also seem to simultaneously stabilize the charge state of the carbon backbone of proteins to resist any further changes in their shape. Theoretically, this allows cellular proteins to live longer and it saves energy on other processes .
Some researchers think that Resveratrol and SIRT1 might make the body more sensitive to vitamin D (potentiate the vitamin D receptor, VDR), but human data are lacking. They are also investigating whether SIRT1 can [5, 6]:
- Inhibit IGF-1 .
- Inhibit mTOR .
- Affect nitric oxide pathways. Good SIRT1 levels and activity are hypothesized to cause nitric oxide to stimulate DNA repair genes (via deacetylation of FoxO1). Otherwise, nitric oxide is thought to stimulate genes that will cause the cell to self-destruct .
- Impact adiponectin release from fat cells. It seems to decrease adiponectin by decreasing PPAR gamma in these cells  butt increase adiponectin by increasing Foxo1 [11, 12, 13].
These pathways haven’t been properly researched in humans.
SIRT 1 and SIRT 3 enzymes are hypothesized to be protective against :
- Neurodegeneration in the brain
- Vascular inflammation, producing damage to blood vessels that can result in stroke or heart attack
- Increased fat storage in the liver, which can lead to fatty liver disease (NAFLD)
- Increased fat production and deposition in white adipose tissue, the primary fat storage form found in dangerous belly fat
- Insulin resistance, preventing cells from appropriately removing glucose from the blood, producing higher blood sugar levels and leading directly to metabolic syndrome
- Fatigue, loss of muscle strength, and fatty infiltration of muscles resulting in reduced fatty acid oxidation (“burning”), thereby depriving muscles of their normal sources of energy
However, the current hypotheses are based mostly on animal and cell-based studies that can’t be applied to humans.
Similarly, SIRT1 is hypothesized to activate (by deacetylation) the following pathways based on animal and cellular data:
- PPAR-alpha, PGC-1a, LXR 
- MAO-A, FOXOs – FOXO1a, Foxo3 
- UCP2, FGF-21 , PXR (overall increase production/activity) [17, 18]
- FXR (deacetylation allows it to bind with RXR-a, DNA binding, and transactivation activity) ; mixed findings, may also inhibit FXR .
If your goal is to increase SIRT1 to improve your neurological issues – including those of cognitive problems, mood imbalances, or serious inflammation – it’s important to talk to your doctor, especially your symptoms are significantly impacting your daily life.
Your doctor should diagnose and treat the condition causing your symptoms.
Therefore, you may try the additional strategies listed below if you and your doctor determine that they could be appropriate. None of these strategies should ever be done in place of what your doctor recommends or prescribes.
Remember that the existing evidence does not suggest that low SIRT1 causes any disorder.
The potential health effects of activating SIRT1 in humans are still an area of research.
Additionally, changes in biochemistry are not something that people can change on their own with the approaches listed below.
Thus, we’re providing a summary of the existing research, which should guide further investigational efforts.
The studies listed in this section were mostly done in animals and should not be interpreted as supportive of health benefits in humans.
Please read through them having all the limitations, caveats, and precautions mentioned above in mind.
Theoretically, factors that may increase NAD+ might also increase SIRT1 activity. Those are covered in this article.
DHA is claimed to increase SIRT1 by modulating the immune system and supporting mitochondrial health. This hasn’t been proven in humans, though .
DHA is hypothesized to increase SIRT1 in blood vessels, which may increase Nitric Oxide (eNOS) .
DHA may increase SIRT1 in the hippocampus, which is hypothesized to reduce cognitive decline. In animals, DHA appears to enhance learning and memory. DHA reversed a reduction in sirt1 levels in rats with mild traumatic brain injury [29, 30].
Epidemiological studies suggest that low blood DHA levels are associated with cognitive deficits in healthy elderly people and in patients with neurodegenerative disorders .
DHA is naturally found in fish, but supplements are also available. However, DHA supplements have not been approved by the FDA for medical use. Supplements generally lack solid clinical research. Regulations set manufacturing standards for them but don’t guarantee that they’re safe or effective. Speak with your doctor before supplementing.
In aged mice, SIRT1 levels in the SCN – viewed by some as the circadian command center – are decreased, as are those of BMAL1 and PER2. Scientists think this leads to a longer circadian period, disrupted activity patterns, and an inability to adapt to light-dark changes in the environment .
Young mice lacking brain SIRT1 have similar effects to these aging-dependent circadian changes, whereas mice that overexpress SIRT1 in the brain appear to be protected from some of the circadian effects of aging .
Human studies are needed to better understand these pathways.
The following supplements, drugs, and pathways are theoretical and anecdotal. They aren’t backed up by solid science. We bring them up for informational purposes.
- Nicotinamide Riboside 
- Zinc 
- Nicotine 
- EGCG/ Tea (cells) 
- PQQ 
- Curcumin 
- Forskolin [43, 44]
- Pterostilbene 
- Vitamin D (active form calcitriol) 
- Lipoic Acid 
- Fisetin 
- Berberine 
- Epimedium/Icariin 
- Pau Darco/Beta Lapachone 
- HMB 
- Gotu Kola 
- Grape Seed Extract 
- Kelp Powder
- LLLT (infrared) 
- Quercetin 
- Bitter melon  – normalizes SIRT1
- Pyruvate 
- Lycopene – metabolite increases SIRT1 production and activity 
- Butein 
Metformin is an anti-diabetic drug that is available only with a doctor’s prescription. Talk to your healthcare provider before taking aspirin or any other over-the-counter (OTC) drug.
Cold and forskolin are hypothesized to increase SIRT1 activity by increasing cyclic AMP and independent of NAD+ levels. This hasn’t been proven. According to a related unverified theory, humans evolved to have this as a more rapid way to activate metabolism than by slowly increasing NAD+ levels [43, 44].
- Adrenaline [43, 44]
- PDE5 inhibitors 
- PON1 , BMAL1 , Other: FOXO3a, c-Myc, PARP inhibition
Scientists are investigating whether the following factors increase NAD+, which may theoretically also increase SIRT1. However, the impact of these factors on NAD+ or SIRT1 in humans is unknown. Much of this research is early, speculative, or of relatively low quality.
- Fasting 
- Calorie restriction 
- Exercise 
- Saunas 
- Nicotinamide Riboside 
- Ketosis/β-hydroxybutyrate 
- Fructose 
- AMPK activation  – AMPK increases SIRT1 activity by increasing cellular NAD+levels (increases NAMPT ). SIRT1 activation also stimulates fatty acid oxidation and indirectly activates AMPK.
- Pau Darco/Beta Lapachone 
- Oxaloacetate 
- Malic acid 
- Resveratrol 
- Apigenin 
- Leucine 
- Niacinamide – low doses 
- Succinic acid, to a lower degree than malic acid 
- Tryptophan and Aspartic acid are fuel for NAD+ , but we usually get enough dietary amino acids if you eat adequate protein.
Scientists say that one way to look at potential SIRt1 negatives is to have the following in mind :
- Most of the time, biology deals with trade-offs. The body attempts to balance SIRT1 activity, so excess activation – like excess inhibition – may have negative health consequences
- SIRT1 effects are tissue-dependent. Even though SIRT1 levels may correlate in one tissue to another, levels are different.
- The cellular environment likely matters. If SIRT1 is high and certain other genes are switched on, SIRT1 may matter. Otherwise, it may not. This is the case with many other pathways in the body.
- SIRT1 levels seem to change in a circadian manner. The impact of chronically high levels is unknown.
Some scientists think that SIRT1 may increase Th17 cells (by deacetylating RORγt), which are mainly inflammatory. Additionally, inhibition of SIRT1 is being researched as a potential way to suppress multiple sclerosis in animals .
Cell-based and animal research suggests that SIRT1 over-activation may:
- Increase the cytokine TNF (in response to LPS), IL-6 and IL-8 in the tissue of patients with rheumatoid arthritis .
- Decrease Nrf2-related gene production since acetylation allows Nrf2 to bind to DNA better and produce antioxidant genes .
- Decrease beta cell proliferation in the pancreas (GLP-1 blocks SIRT1 deacetylation of FoxO1) . Beta cells release insulin; reduced beta cells are implicated in diabetes. On the other hand, SIRT1 may impact other anti-diabetic pathways.
- Inhibit DNA repair enzymes (including p53, BRCA1&2, Ku70) and apoptosis proteins . It deacetylates p53, which decreases its activity .
- Lower IGF-1 and its receptors, which may affect neuronal survival .
- Impair liver regeneration to a degree .
- More SIRT1 in CD4+ cells has been linked with Lupus [80, 81].
Human data are lacking.
SIRT1 inhibition with nicotinamide is being investigated as an anti-tumor target in cells. We can’t draw any conclusions from cell-based research .
The following pathways are hypothesized to inhibit SIRT1 in cells or animals:
- PPAR gamma
- Melatonin [77, 83]
- IGF-1 
- IFNy [84, 85], CIITA 
- Nicotinamide – at higher doses 
- CLA (supplement) 
- Genistein 
- Trichostatin 
Human data are lacking.
It’s thought that the C allele causes increased gene production of SIRT1, but the evidence is limited .
TT was linked with diabetes .
More research on these genetic variations is needed.